ALZ-101 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for ALZ-101 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Alzheimer Disease. Most recent publication: Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial., Alzheimers Res Ther, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
    Lovró Z, Sandberg A, Zetterberg H, et al. · Alzheimers Res Ther · 2026
    PubMed: PMID 42157213 · NCT05328115 · Alzheimer Disease

Publications by year

20262026: 1 publications.

2026
1

Publications by indication

Alzheimer Disease (1)

  • Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
    Alzheimers Res Ther · 2026 · PMID 42157213 · NCT05328115

Publications by journal

All ALZ-101 publications (1)

2026 (1 paper)

  1. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
    Lovró Z, Sandberg A, Zetterberg H, et al. · Alzheimers Res Ther · 2026 · Derived
    PubMed: PMID 42157213 · NCT05328115 · Alzheimer Disease

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).